Corrected QT (QTc) Study With Flucticasone Furoate and GW642444

Exclusion Criteria

• •Subject is deemed unsuitable for the study.
• •A screening Holter ECG tracing that reveals clinically concerning arrhythmias
• •A supine blood pressure that is persistently higher than 140/90 millimetres of mercury (mmHg) at screening.
• •A supine mean heart rate outside the range 40-90 beats per minute (bpm) at screening.
• •History or presence of any medically significant disease or disorder, in particular, a family history of QT prolongation, of early or sudden cardiac death or of early cardiovascular disease.
• •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• •The subject has any history of breathing problems in adult life.
• •Subjects who have suffered an upper or lower respiratory tract infection within 4 weeks of the screening visit.
• •Pregnant females.
• •Lactating females.
• •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
• •A positive test for Human Immunodeficiency Virus (HIV) antibody.
• •The subject has taken inhaled, intranasal or topical steroids less than 4 weeks before the screening visit.
• •Positive carbon monoxide (CO) or alcohol breath test at screening or on admission to the Unit.
• •Positive urine cotinine test at screening.
• •History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of \>21 units for males or \>14 units for females.
• •The subject has participated in a clinical trial in the last 3 months.
• •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days of the first dose.
• •The subject has taken oral corticosteroids less than 8 weeks before the screening visit.
• •History of sensitivity to any of the study medications.
• •History of milk protein allergy.
• •Where participation in the study would result in donation of blood or blood products in excess of 500 millilitres (mL) within a 90 day period.
• •Unwillingness or inability to follow the procedures outlined in the protocol.
• •Subject is mentally or legally incapacitated.
• •Consumption of seville oranges, pommelos (members of the grapefruit family) or grapefruit juice from 7 days prior to the first dose of study medication.